哌嗪二酮用于转移性肉瘤的II期试验。
Phase II trial of piperazinedione in metastatic sarcoma.
作者信息
Presant C A, Bartolucci A A
出版信息
Am J Clin Oncol. 1982 Apr;5(2):185-7. doi: 10.1097/00000421-198204000-00067.
Abstract
Thirty-five patients with metastatic sarcomas received piperazinedione 9 mg/m2 every 3 weeks. Of 27 evaluable patients, 3 patients had stable disease for at least 6 weeks. The dose-limiting toxicity was myelosuppression. Piperazinedione is inactive in patients with drug-resistant metastatic sarcomas.
摘要
35例转移性肉瘤患者每3周接受9mg/m²的哌嗪二酮治疗。在27例可评估的患者中，3例患者疾病稳定至少6周。剂量限制性毒性为骨髓抑制。哌嗪二酮对耐药转移性肉瘤患者无效。
Zotero 插件